Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

Authors:
  • DSDavid A. Smith
    David A. Smith
  • PCPaul Conkling
    Paul Conkling
  • DRDonald A. Richards
    Donald A. Richards
  • MFMaria Regina C. Flores
    Maria Regina C. Flores
  • TBThomas E. Boyd
    Thomas E. Boyd
  • AMAlain C. Mita
    Alain C. Mita
  • GBGuillaume de La Bourdonnaye
    Guillaume de La Bourdonnaye
  • DWDavid Wages
    David Wages
  • ABAlice S. Bexon
    Alice S. Bexon
Publisher website
Google Scholar
Abstract
No abstract available